SRPK1、IGF2BP3在肝癌组织中的表达及临床意义

摘要/Abstract

摘要： 目的探究丝氨酸精氨酸蛋白激酶1(SRPK1)、胰岛素样生长因子2-mRNA结合蛋白3(IGF2BP3)在肝癌组织中的表达及临床意义。方法选取2019年3月至2021年3月连云港市第一人民医院诊治的118例肝癌患者手术中留存的癌组织标本和癌旁组织标本进行研究。采用免疫组织化学法检测SRPK1、IGF2BP3蛋白表达水平;采用多因素Cox回归分析SRPK1、IGF2BP3表达与临床病理特征和患者预后的关系。结果与癌旁组织(32.20%、28.81%)相比,肝癌组织中SRPK1、IGF2BP3的阳性表达率(72.88%、75.42%)明显升高(χ²=39.16,P<0.001;χ²=51.36,P<0.001)。TNM分期为Ⅲ~Ⅳ期(76.74%、74.16%)、肿瘤直径＞5 cm(81.40%、79.78%)、低分化程度(40.70%、37.08%)及发生淋巴结转移(67.44%、60.67%)患者的肝癌组织SRPK1阳性表达、IGF2BP3阳性表达比例明显升高(均P<0.05)。肝癌组织中SRPK1阴性表达患者3年生存率(78.13%)较高(χ²=31.416,P<0.001);IGF2BP3阴性表达患者3年生存率(82.76%)较高(χ²=30.763,P<0.001)。SRPK1(HR=2.16;95%CI:1.16~4.00;P=0.015)、IGF2BP3(HR=2.14;95%CI:1.05~4.36;P=0.035)、TNM分期(HR=2.25;95%CI:1.20~4.21;P=0.012)、分化程度(HR=2.36;95%CI:1.21~4.61;P=0.012)、淋巴结转移(HR=2.39;95%CI:1.07~5.31;P=0.033)是肝癌患者预后的影响因素(P<0.05)。结论 SRPK1和IGF2BP3在肝癌组织中阳性表达率升高,其与淋巴结转移、TNM分期、分化程度及预后密切相关。

关键词: 肝癌组织, SRPK1, IGF2BP3, 预后

Abstract: Objective To investigate the expression and clinical significance of serine arginine protein kinase 1 (SRPK1) and insulin-like growth factor 2-mRNA binding protein 3 (IGF2BP3) in liver cancer tissue. Methods A total of 118 patients with liver cancer who treated in the Lianyungang First People′s Hospital from March 2019 to March 2021 were selected for the study. Immunohistochemical methods were applied to detect the expression levels of SRPK1 and IGF2BP3 proteins. Multivariate Cox regression was used to analyze the relationship between SRPK1 and IGF2BP3 expression, clinicopathological features and prognosis of patients. Results The positive expression rates of SRPK1 and IGF2BP3 in liver cancer tissues (72.88%, 75.42%) were significantly higher than those in adjacent tissues (32.20%, 28.81%) (χ²=39.16, P<0.001; χ²=51.36, P<0.001). The positive expression of SRPK1 and IGF2BP3 were found in patients with TNM stage Ⅲ to Ⅳ (76.74%, 74.16%), tumor diameter > 5 cm (81.40%, 79.78%), low differentiation (40.70%, 37.08%) and lymph node metastasis (67.44%, 60.67%). The proportion of positive expression was significantly increased (all P<0.05). The 3-year survival rate (78.13%) of patients with SRPK1 negative expression was higher (χ²=31.416, P<0.001). The 3-year survival rate (82.76%) of patients with IGF2BP3 positive expression was higher (χ²=30.763, P<0.001). SRPK1(HR=2.16; 95%CI:1.16~4.00; P=0.015), IGF2BP3(HR=2.14; 95%CI:1.05~4.36; P=0.035), TNM staging (HR=2.25; 95%CI:1.20~4.21; P=0.012), differentiation degree (HR=2.36; 95%CI:1.21~4.61; P=0.012), lymph node metastasis (HR=2.39; 95%CI:1.07~5.31; P=0.033) were the prognostic factors of patients with liver cancer (P<0.05). Conclusion The positive expression rates of SRPK1 and IGF2BP3 are increased in liver cancer tissues, which are closely related to differentiation degree, TNM staging, lymph node metastasis, and prognosis.

Key words: Hepatic cancer tissues, SRPK1, IGF2BP3, Prognosis

胡方雨, 王玺荣, 汪海清. SRPK1、IGF2BP3在肝癌组织中的表达及临床意义[J]. 肝脏, 2026, 31(8): 1124-1128.

Hu Fangyu, Wang Xirong, Wang Haiqing. Expression and clinical significance of SRPK1 and IGF2BP3 in liver cancer tissue[J]. Chinese Hepatolgy, 2026, 31(8): 1124-1128.

/ 推荐

参考文献

[1] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J].国际肿瘤学杂志, 2024, 51(7):385-410.
[2] Demir T, Lee S S, Kaseb A O. Systemic therapy of liver cancer[J]. Adv Cancer Res, 2021, 149(1):257-294.
[3] Piñero F, Dirchwolf M, Pessôa M G. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment[J]. Cells, 2020, 9(6):1370.
[4] Huang J Q, Li H F, Zhu J, et al. SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-κB activation in colon cancer[J]. J Transl Med, 2021, 19(1):280.
[5] Belali T, Wodi C, Clark B, et al. WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1[J]. Biochim Biophys Acta Gene Regul Mech, 2020, 1863(12):194642.
[6] Sun C Y, Cao D, Du B B, et al. The role of insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m6A readers in cancer[J]. Int J Biol Sci, 2022, 18(7):2744-2758.
[7] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华消化外科杂志, 2017, 16(7):705-720.
[8] 陈焱, 宋小平, 汤小虎, 等. C-met蛋白在食管癌组织中的表达及其与临床特征的关系[J]. 癌症进展, 2018, 16(4):472-474.
[9] Duggan W P, O′Connell E, Prehn J H M, et al. Serine-arginine protein kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis[J]. Mol Cell Biochem, 2022, 477(10):2451-2467.
[10] Wang C, Zhou Z, Subhramanyam C S, et al. SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells[J]. Commun Biol, 2020, 3(1):268.
[11] Wang Q, Wang G T, Lu W H. MiR-155 inhibits malignant biological behavior of human liver cancer cells by regulating SRPK1[J]. Technol Cancer Res Treat, 2021, 20(1):1-8.
[12] 石永杰, 陈旖鹛, 黄思聪, 等. SRPK1激活Wnt/β-catenin通路促进肝癌细胞上皮间充质转化[J]. 西部医学, 2023, 35(7):951-958.
[13] Liu X, Chen J, Chen W, et al. Targeting IGF2BP3 in cancer[J]. Int J Mol Sci, 2023, 24(11):9423.
[14] Chen P, Xu J, Cui Z, et al. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer[J]. Front Immunol, 2023, 14(1):1071675.
[15] Huang W, Li Y, Zhang C, et al. IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signalling pathway in human bladder cancer[J]. J Cell Mol Med, 2020, 24(23):13949-13960.
[16] Zhang B, Tang B, Lv J, et al. Systematic analyses to explore immune gene sets-based signature in hepatocellular carcinoma, in which IGF2BP3 contributes to tumor progression[J]. Clin Immunol, 2022, 241(1):109073.